pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,618 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints610BioPharma Dive235onclive165Fierce Biotech79BioSpace78raps32globenewswire health26fda recalls
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
    A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer'…
    Endpoints · 1mo ago↗ source
  • Opinion: The virtual end of the doctor’s office waiting room
    It’s time to rethink and redesign how patients enter the health care system altogether, writes emergency physician Iyesatta Massaquoi Emeli.
    STAT · 1mo ago↗ source
  • STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
    Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer telehealth businesses.
← prev
page 36 of 65
next →
20
fda press20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 1mo ago
↗ source
  • STAT+: Trump administration releases rules for new Medicaid work requirements
    States are racing to implement the new requirements by the start of next year.
    STAT · 1mo ago↗ source
  • STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
    Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
    STAT · 1mo ago↗ source
  • STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding
    With no licensed vaccines available to protect against the Ebola virus currently spreading in the Congo, efforts are underway to fast-track development of at least three vaccines.
    STAT · 1mo ago↗ source
  • STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
    Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
    STAT · 1mo ago↗ source
  • STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
    Here is some of what you may have missed from the world's largest cancer research meeting.
    STAT · 1mo ago↗ source
  • STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
    At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.
    STAT · 1mo ago↗ source
  • The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
    How much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The FD…
    Endpoints · 1mo ago↗ source
  • Epigenetic editing shows promise against chronic hep B infections
    A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therape…
    Endpoints · 1mo ago↗ source
  • Shionogi wins US approval for first pill to prevent Covid following exposure
    Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...
    Endpoints · 1mo ago↗ source
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    Endpoints · 1mo ago↗ source
  • As FDA misses deadline on electric shock ban, disability advocates speak out
    The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual disabilities.
    STAT · 1mo ago↗ source
  • STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
    We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.
    STAT · 1mo ago↗ source
  • Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
    🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
    CHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
    Endpoints · 1mo ago↗ source
  • After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
    Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
    Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
    STAT · 1mo ago↗ source
  • Opinion: What should hospitals do when patients demand unvaccinated donor blood?
    “You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about requests for unvaccinated donor blood.
    STAT · 1mo ago↗ source
  • STAT+: A turning point for pancreatic cancer patients
    Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • CDC says containing the spread of Ebola is top priority
    The Trump administration disregards infectious disease playbook, CEPI offers vaccine funding, and other health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Turn Therapeutics' eczema drug shows rapid response in mid-stage data
    California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of…
    Endpoints · 1mo ago↗ source
  • Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
    Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…
    Endpoints · 1mo ago↗ source
  • STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
    The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
    STAT · 1mo ago↗ source